Figure 3
Anti-CD137 mAb efficacy is time dependent. BALB/c mice were inoculated subcutaneously with 5 × 106 A20 tumor cells. Mice received either no treatment (● and 
) or 1 intraperitoneal injection of anti-CD137 mAb (■ and —) at various time points after tumor inoculation: day 0, day 3, day 6, or day 9. Mice (10 per group) were monitored for tumor growth (A, mean ± SEM) and overall survival (B).
